Extended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unit

被引:18
作者
Cumpston, A. [1 ,2 ]
Craig, M. [3 ]
Hamadani, M. [3 ]
Abraham, J. [3 ]
Hobbs, G. R. [4 ]
Sarwari, A. R. [5 ]
机构
[1] West Virginia Univ Healthcare, Dept Pharm, Morgantown, WV 26506 USA
[2] West Virginia Univ Healthcare, MBRCC, Morgantown, WV 26506 USA
[3] W Virginia Univ, MBRCC, Osborn Hematopoiet Malignancy & Transplantat Prog, Morgantown, WV 26506 USA
[4] W Virginia Univ, Dept Stat, Morgantown, WV 26506 USA
[5] W Virginia Univ, Dept Med, Infect Dis Sect, Morgantown, WV 26506 USA
关键词
neutropenic fever; antibiotic cycling; leukemia; hematopoietic cell transplantation; bacterial resistance; INFECTIOUS-DISEASES-SOCIETY; CLINICAL-PRACTICE; CANCER; EXPERIENCE; RESISTANCE; AMERICA;
D O I
10.1111/tid.12035
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Febrile neutropenia is a common complication during treatment of hematological malignancies and hematopoietic cell transplantation. Empiric antibiotic therapy in this setting, while standard of care, commonly leads to microbial resistance. We have previously shown that cycling antibiotics in this patient population is feasible. This report provides long-term follow-up of cycling antibiotics in this patient population. Methods In a prospective cohort of hematological malignancy patients with neutropenic fever, we sought to evaluate the role of empiric antibiotic cycling in preventing antibiotic resistance. Antibiotic cycling was initiated in March 2002 and, until June 2005, antibiotics were cycled every 8months (Cycling Period A). From July 2005 to December 2009, antibiotics were cycled every 3months (Cycling Period B). The rates of bacteremia, resistance, and complications were compared to a retrospective cohort (Pre-cycling Period). Results The rate of gram-negative bacteremia decreased when compared to Cycling Periods A and B (5.3 vs. 2.1 and 3.3 episodes/1000 patient-days, respectively, P<0.0001), most likely owing to implementation of quinolone prophylaxis. The resistance profile of the gram-negative organisms isolated remained stable over the 3 time periods, with the exception of an increase in quinolone resistance during the cycling periods. Gram-positive bacteremia rates remained stable, but vancomycin-resistant Enterococcus (VRE) increased significantly (0.1 vs. 1.0 and 1.6 episodes/1000 patient-days, respectively, P=0.005) during cycling periods. Mortality rates were comparable. Conclusions Antibiotic cycling for neutropenic fever was effectively implemented and followed over an extended time period. Gram-negative resistance remained stable, but there is some concern for selection of resistant gram-positive bacteria, specifically VRE. Although antibiotic cycling did not seem to cause resistance in our study, further study is necessary to clarify the effect of cycling on antibiotic resistance, patient outcomes, and hospital cost.
引用
收藏
页码:142 / 149
页数:8
相关论文
共 14 条
[1]   Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia [J].
Biron, P ;
Fuhrmann, C ;
Cure, H ;
Viens, P ;
Lefebvre, D ;
Thyss, A ;
Viot, M ;
Soler-Michel, P ;
Rollin, C ;
Grès, JJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (04) :511-518
[2]   Antibiotic cycling or rotation: a systematic review of the evidence of efficacy [J].
Brown, EM ;
Nathwani, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (01) :6-9
[3]   Antibiotic cycling to decrease bacterial antibiotic resistance: a 5-year experience on a bone marrow transplant unit [J].
Cadena, J. ;
Taboada, C. A. ;
Burgess, D. S. ;
Ma, J. Z. ;
Lewis, J. S., II ;
Freytes, C. O. ;
Patterson, J. E. .
BONE MARROW TRANSPLANTATION, 2007, 40 (02) :151-155
[4]   The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit [J].
Craig, M. ;
Cumpston, A. D. ;
Hobbs, G. R. ;
DeVetten, M. P. ;
Sarwari, A. R. ;
Ericson, S. G. .
BONE MARROW TRANSPLANTATION, 2007, 39 (08) :477-482
[5]   CEFTAZIDIME COMPARED WITH PIPERACILLIN AND TOBRAMYCIN FOR THE EMPIRIC TREATMENT OF FEVER IN NEUTROPENIC PATIENTS WITH CANCER - A MULTICENTER RANDOMIZED TRIAL [J].
DEPAUW, BE ;
DERESINSKI, SC ;
FELD, R ;
LANEALLMAN, EF ;
DONNELLY, JP .
ANNALS OF INTERNAL MEDICINE, 1994, 120 (10) :834-844
[6]   Once-daily dosing of aminoglycosides: review and recommendations for clinical practice [J].
Freeman, CD ;
Nicolau, DP ;
Belliveau, PP ;
Nightingale, CH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 (06) :677-686
[7]  
Freifeld AG, 2011, CLIN INFECT DIS, V52, pE56, DOI 10.1093/cid/cir073
[8]   Antimicrobial cycling: Lessons learned from the aminoglycoside experience [J].
Gerding, DN .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2000, 21 (01) :S12-S17
[9]   The microbial genetics of antibiotic cycling [J].
John, JE ;
Rice, LB .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2000, 21 (01) :S22-S31
[10]   Antibiotic cycling: more than it might seem? [J].
Masterton, RG .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (01) :1-5